Ernexa Therapeutics Inc. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d594a4f1-10a0-4407-9d61-bd3843148317/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-14.1M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-010102 |
| FY 2024 | $-44.5M | 2024-01-01 – 2024-12-31 | evidence 0001493152-25-010051 |
| FY 2023 | $-21.7M | 2023-01-01 – 2023-12-31 | evidence 0001140361-24-013254 |
| FY 2022 | $-24.6M | 2022-01-01 – 2022-12-31 | evidence 0001140361-23-012418 |
| FY 2021 | $-122.5M | 2021-01-01 – 2021-12-31 | evidence 0001140361-22-024668 |
| FY 2020 | $-7.3M | 2020-01-01 – 2020-12-31 | evidence 0001140361-22-024668 |
| FY 2019 | $-2.0M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-004343 |
| FY 2018 | $-259.0k | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-003770 |
| FY 2017 | $-1.1M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-003164 |
| FY 2016 | $-2.9M | 2016-01-01 – 2016-12-31 | evidence 0001493152-17-002280 |
| FY 2015 | $-7.2M | 2015-01-01 – 2015-12-31 | evidence 0001493152-16-008049 |
| FY 2014 | $-5.0M | 2014-01-01 – 2014-12-31 | evidence 0001019687-15-001115 |
| FY 2013 | $-1.1M | 2013-01-01 – 2013-12-31 | evidence 0001019687-14-001135 |
| FY 2012 | $-995.0k | 2012-01-01 – 2012-12-31 | evidence 0001019687-13-001065 |
| FY 2011 | $-3.4M | 2011-01-01 – 2011-12-31 | evidence 0001019687-12-001146 |
| FY 2010 | $-400.0k | 2010-01-01 – 2010-12-31 | evidence 0001019687-12-001146 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Ernexa Therapeutics Inc. — all facts · Revenue · Operating Income